The LiBBY trial found that a purified twice-daily THC/CBD oil reduced agitation in hospice-eligible people with late-stage dementia. People with mild cognitive impairment (MCI), early memory or thinking change with daily function largely intact, were not studied but can use the findings to ask focused questions about future research.
LiBBY, short for Life's End Benefits of cannabidiol and tetrahydrocannabinol, was a Phase 2 trial that reported topline results July 14, 2026 at AAIC 2026 in London, according to the Alzheimer's Association in the Alzheimer's Association release. The study enrolled 120 participants across 10 U.S. sites, with visits in homes and residences.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What treatment did researchers test?
- How much did agitation change?
- What safety issues appeared?
- What can someone with MCI ask a clinician?
What treatment did researchers test?
The drug was called T2:C100. It held 2 mg THC plus 100 mg CBD in digestible oil and was given twice daily. The formula was rapid-acting and purified. It was distinct from dispensary products, according to the study team in the LiBBY Study results page.
That distinction matters because dose and delivery affect both benefit and risk. Participants had Alzheimer's or another dementia with significant agitation. They were hospice-eligible, with a mean age of 80, and 55% were female. The trial was multicenter, randomized, double-blind, and placebo-controlled.
How much did agitation change?
Agitation was measured with the Cohen-Mansfield Agitation Inventory. It rates restlessness, shouting, hitting, pacing, and similar behaviors. Scores fell more with THC/CBD than placebo at week 2, by 10.61 points versus 4.35 points, and the gap held through 12 weeks, as reported from Dr. Jacobo Mintzer's presentation in the MIMS report on the AAIC presentation.
A larger drop means fewer or milder agitation behaviors. Clinicians also rated overall change. At week 2, 83.9% improved on treatment versus 30.5% on placebo. At week 12, 87.2% improved versus 23.6% on placebo.
What safety issues appeared?
Overall adverse events were comparable between groups. Serious events were higher with THC/CBD. Serious events occurred in 23.3% on treatment versus 11.9% on placebo, driven by serious infections at 11.7% versus 1.7%, with more deaths at 13.1% versus 5.1%, according to NeurologyLive in the NeurologyLive report.
This was a frail, end-of-life population. For readers, the lesson is narrow. Benefit came with added serious medical risk in very ill patients. Results do not transfer to healthier groups or to other products.
What can someone with MCI ask a clinician?
MCI was not part of LiBBY. The findings apply only to the studied dose and delivery system.
They do not support using other cannabis, marijuana, or over-the-counter CBD for agitation. Bring the trial printout and ask how late-stage agitation differs from MCI symptoms. Ask whether any future trial will include earlier stages, what safety monitoring it would use, and what non-drug options fit now.
- Was I excluded from LiBBY-like research because I have MCI, not hospice-eligible dementia with agitation?
- Would a future cannabinoid study ever suit my health history and infection risk?
- How would researchers separate expected benefit from serious illness already present near end of life?
- What sleep, routine, hearing, vision, pain, and caregiver-support steps could lower distress today?
You Might Also Like
- AAIC 2026 LiBBY THC-CBD Agitation Trial: Questions People With Mild Cognitive Impairment Can Ask About the Research
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: Practical Evidence-Based Steps for People With Mild Cognitive Impairment
